Symrise shares surged 6% in early European trading after the German chemical group announced its first-ever share buyback program. The €400 million repurchase, representing roughly 4% of its market capitalization, is fueled by strong free cash flow and expected proceeds from portfolio actions. CEO Jean-Yves Parisot stated the company is in an excellent position to invest in strategic priorities while returning excess capital to shareholders.

However, analysts at Kepler Cheuvreux view the move as a "consolation" for significant recent impairments totaling €295 million. The company faces a €145 million non-cash charge related to its terpenes business and a €150 million hit from its investment in Swedencare. These charges follow two profit warnings in 2025, which Symrise attributed to tepid consumer demand and broader economic headwinds.

While the buyback offers investor support, it coincides with ongoing challenges for the fragrance maker.